Analyse-Technique.net - Toutes les news de l'analyse technique

Categories


Tags

Catégorie - MERCK KGAA

MERCK KGAA - 100809,1354,merck,kgaa,tendance,baissiere,peut,reprendrecommuniques 10/08/09 13:54 MERCK KGAA : La tendance baissière peut reprendreCOMMUNIQUES
SYNTHESE Le MACD est négatif et inférieur à sa ligne de signal. Cette configuration dégrade les perspectives sur le titre. Le RSI n'indique pas encore une survente donc la poursuite de la baisse est techniquement possible.
2009-08-10 - TF1

MERCK KGAA - sanofi,aventis,candidat,reprise,dinova,pharmaceuticals Sanofi-Aventis : candidat à la reprise d'iNova Pharmaceuticals ?
Sanofi-Aventis et Merck KgaA pourraient bien faire partie des candidats à la reprise de iNova Pharmaceuticals... Sanofi-Aventis et Merck KgaA pourraient bien faire partie des ...
2009-11-02 - Le Revenu

MERCK KGAA - boursefrancfort,forte,hausse,dax,152,sauf,merck,kgaa BOURSE/Francfort en forte hausse (Dax +1,52%), sauf Merck KGaA ...
Francfort (awp/afp) - La Bourse de Francfort était en forte hausse lundi, de nouveau plus confiante pour la Grèce, mais Merck KGaA reculait après l'annonce ...
2010-03-01 - Romandie.com

MERCK KGAA - millipore,forte,hausse,ny,apres,loffre,merck,kgaa Millipore: en forte hausse à NY après l'offre de Merck KGaA.
(CercleFinance.com) - Millipore était en forte hausse lundi à la Bourse de New York après avoir reçu pendant le week-end une offre de rachat de la part de l'allemand Merck KGaA.
2010-03-01 - Cerclefinance

MERCK KGAA - merck,issues,years,biggest,euro,company,bond,to,fund,millipore Merck Issues Year’s Biggest Euro Company Bond to Fund Millipore
March 17 (Bloomberg) -- Merck KGaA is selling 3.2 billion euros ($4.4 billion) of bonds in Europe’s biggest corporate issue this year as the German chemical and drug maker seeks to refinance its takeover of Millipore Corp.
2010-03-17 - Bloomberg

MERCK KGAA - merck,kgaa,suspends,stimuvax,studies,on,side,effect,update6 Merck KGaA Suspends Stimuvax Studies on Side Effect (Update6)
March 23 (Bloomberg) -- Merck KGaA stopped studies of the experimental cancer vaccine Stimuvax, a shot that the German drugmaker has said may generate as much as $1 billion in sales, after a patient with a blood malignancy developed a brain infection while taking it.
2010-03-23 - Bloomberg

MERCK KGAA - afx,uk,focus,2010,03,23,0753,update,1,merck,kgaa,suspends,stimuvax,cancer,vaccine,trials (AFX UK Focus) 2010-03-23 07:53 UPDATE 1-Merck KGaA suspends Stimuvax cancer vaccine trials
FRANKFURT, March 23 (Reuters) - German drugmaker Merck KGaA put on hold all testing on humans of its experimental cancer vaccine Stimuvax after a Phase II trial participant contracted encephalitis. The patient was taking part in a trial arm whose participants received Stimuvax in combination with the chemotherapeutic agent cyclophosphamide, which is not used in the other Stimuvax studies, Merck ...
2010-03-23 - Interactive Investor

MERCK KGAA - test,predicts,which,patients,benefit,from,6,billion,ms,drugs Test Predicts Which Patients Benefit From $6 Billion MS Drugs
Multiple sclerosis drugs from Biogen Idec Inc., Merck KGaA and Bayer AG with sales of $6.1 billion work for fewer than 3 in 4 patients and a test can predict which ones, a study found.
2010-03-28 - BusinessWeek

MERCK KGAA - erbitux,can,now,be,used,in,japan,as,1st,line,treatment,for,mcrc,merck,serono Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.
2010-03-29 - News-Medical-Net

MERCK KGAA - mercks,erbitux,granted,extended,use,in,japan,for,1st,line,treatment,of,mcrc,patients,with,kras,wild,type,tumours Merck's Erbitux granted extended use in Japan for 1st-line treatment of mCRC patients with KRAS wild-type tumours
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that Erbitux (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor (EGFR)-expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer (mCRC) carrying the KRAS wildtype gene.
2010-03-30 - PharmaBiz

MERCK KGAA - merck,serono,survey,shows,the,number,of,mcrc,patients,tested,for,kras,jumped,50,in,12,months Merck Serono: Survey Shows The Number Of MCRC Patients Tested For KRAS Jumped 50% In 12 Months
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has revealed new results from a global survey demonstrating that 66% of patients with metastatic colorectal cancer (mCRC) are now tested for KRAS to determine if they could benefit from a personalized therapy, such as Erbitux® (cetuximab). This represents a 50% increase in levels of KRAS testing in just one year...
2010-07-04 - Medical News Today

MERCK KGAA - germanys,merck,sees,q2,profit,rise,69,percent Germany's Merck sees Q2 profit rise 69 percent
(AP:BERLIN) German drug and chemical maker Merck KGaA said Thursday that its second-quarter earnings were up 69 percent, led higher by healthy performances at its liquid crystals business and the Merck Serono pharmaceutical division.
2010-07-29 - INO News

MERCK KGAA - emd,serono,inc,fda,grants,priority,review,to,cladribine,tablets,for,the,treatment,of,relapsing,forms,of,ms EMD Serono, Inc.: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS
ROCKLAND, Mass., July 28 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS). The application also has been granted a Priority Review designation by the FDA, which ...
2010-07-28 - redOrbit

MERCK KGAA - google,leads,revival,in,commercial,paper,as,rates,tumble,credit,markets Google Leads Revival in Commercial Paper as Rates Tumble: Credit Markets
Google Inc. , owner of the most popular Internet search engine, and Germany’s Merck KGaA are leading a revival in commercial paper as nonfinancial companies grab the biggest share of the $1.1 trillion U.S. market from banks since 2002 amid lower borrowing costs.
2010-08-15 - Bloomberg

MERCK KGAA - google,leading,revival,in,commercial,paper,credit,markets Google Leading a Revival in Commercial Paper: Credit Markets
Google Inc., owner of the most popular Internet search engine, and Germany’s Merck KGaA are leading a revival in commercial paper as nonfinancial companies grab the biggest share of the $1.1 trillion U.S. market from banks since 2002 amid lower borrowing costs.
2010-08-15 - BusinessWeek

MERCK KGAA - google,leading,revival,in,commercial,paper Google Leading a Revival in Commercial Paper
Google Inc., owner of the most popular Internet search engine, and Germany’s Merck KGaA are leading a revival in commercial paper as nonfinancial companies grab the biggest share of the $1.1 trillion U.S. market from banks since 2002 amid lower borrowing costs.
2010-08-16 - BusinessWeek

MERCK KGAA - ms,lifelines,reaches,milestone,of,servicing,one,million,in,bound,calls MS LifeLines reaches milestone of servicing one million in-bound calls
EMD Serono, Inc. and Pfizer Inc. announced that MS LifeLines, an educational and support service which includes a call centre, has achieved a milestone in servicing one million in-bound calls since its inception in 2002. MS LifeLines is sponsored by EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. The service is available to the multiple sclerosis (MS) community ...
2010-09-03 - PharmaBiz

MERCK KGAA - valeur,jour,europe,merck,penalise,par,avis,negatif La valeur du jour en Europe - MERCK pénalisé par un avis négatif
(AOF) - Merck KGaA chute de 9,29% à 63,66 euros à la Bourse de Francfort, pénalisé par l'avis négatif des autorités sanitaires européennes pour son ...
2010-09-24 - TF1

MERCK KGAA - merck,kgaa,chute,bourse,apres,revers,sur,traitement,contre,sclerose,plaques Merck KGaA chute en Bourse après un revers sur un traitement contre la sclérose en plaques :
Le laboratoire allemand Merck KGaA chutait vendredi matin en bourse, après un avis négatif des autorités sanitaires européennes à la commercialisation d'un traitement par voie orale de la sclérose en plaques, dans lequel il place de grands espoirs.
2010-09-24 - Boursorama

MERCK KGAA - merck,kgaa,ms,pill,rejected,by,european,drug,agency Merck KGaA MS Pill Rejected by European Drug Agency
European regulators rejected Merck KGaA’s multiple sclerosis pill cladribine, the second setback this week for the German drugmaker in the race with Novartis AG for a share of a new market.
2010-09-24 - BusinessWeek

MERCK KGAA - zacks,analyst,blog,highlights,novartis,ag,merck,kgaa,biogen,idec,teva,and,bed,bath,beyond Zacks Analyst Blog Highlights: Novartis AG, Merck KGaA, Biogen Idec, Teva and Bed Bath & Beyond
CHICAGO--(BUSINESS WIRE)--Zacks.com Analyst Blog features: Novartis AG (NYSE: NVS), Merck KGaA (NYSE: MRK), Biogen Idec (Nasdaq: BIIB), Teva (Nasdaq: TEVA) and Bed Bath & Beyond Inc. (Nasdaq: BBBY). Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579 Here are highlights from Thursday’s ...
2010-09-25 - Business Wire

MERCK KGAA - valeur,jour,europe,merck,kgaa,penalise La valeur du jour en Europe - MERCK KGaA pénalisé ...
(AOF) - En repli de 1,33% à 60,65 euros, le groupe pharmaceutique allemand Merck KGaA accuse la plus forte baisse du DAX 30, l'indice phare de la Bourse de Francfort. Les ...
2010-10-11 - Boursorama

MERCK KGAA - valeur,jour,europe,merck,kgaa,penalise,par,cladribine La valeur du jour en Europe - MERCK KGaA pénalisé par Cladribine
(AOF) - En repli de 1,33% à 60,65 euros, le groupe pharmaceutique allemand Merck KGaA accuse la plus forte baisse du DAX 30, l'indice phare de la Bourse de ...
2010-10-11 - TF1